Afamelanotide
Approved only for EPP; not approved for tanning anywhere.
The licensed relative of the tanning injections: a slow-release implant that raises protective skin pigment, approved only for one rare light-sensitivity disease. A made by Clinuvel, also called Scenesse and Melanotan I.
What the evidence shows
Side effects and risks
Who should avoid it: Cosmetic tanning. It is not approved for that anywhere.
How it works
- Where it acts
- Melanocortin-1 receptors on the skin's pigment cells.
- What it changes
- More eumelanin, the dark pigment that protects skin from light.
- What people notice
- For people with EPP, darker skin and more time in daylight without pain. Nausea and headache occur.
How it is given
A 16 mg implant placed under the skin every two months by a trained professional. The EU limits it to four implants a year.
Getting it in the United States
The legal route for Afamelanotide
Get a prescription from a licensed clinician. Fill it at a licensed pharmacy or through the maker's own direct service.
Routes people use for any peptide in the United States
Telehealth prescribing
Online clinics prescribe after a questionnaire, sometimes with no live doctor visit, and mail the drug. FDA moved in February 2026 to restrict mass-marketed compounded copies and claims that they are generic equivalents.
Risk: Thin medical screening. Compounded versions are not reviewed by FDA for quality.
Covers: Approved GLP-1 drugs, compounded semaglutide and tirzepatide
Source: GZERO Media, Apr 2026
Clinical trial enrolment
The only lawful way to get an unapproved peptide drug with medical monitoring. ClinicalTrials.gov lists eligibility, sites and phone numbers. Researchers note recruitment is hard when people can buy the drug on the gray market instead of risking placebo.
Risk: Possible placebo assignment, strict eligibility and travel to a study site.
Covers: Investigational peptide drugs still in development
Source: NIH, finding a clinical trial
Routes people use for any peptide in the United States
Compounding pharmacy with prescription
A clinician prescribes and a pharmacy compounds. Twelve peptides left the FDA do-not-compound category in April 2026 and a panel backed six in July, but they are not yet formally eligible. Pharmaceutical-grade ingredient is scarce.
Risk: Legal status is unsettled until FDA rulemaking ends. Pharmacies may use research-grade ingredient.
Covers: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon and similar
Source: Frier Levitt, Apr 2026
Med spas and weight-loss clinics
Very common. Secret shoppers called 75 clinics and med spas in two states after shortages ended. 92 percent offered compounded semaglutide and 87 percent tirzepatide, often mixed with B vitamins to look custom.
Risk: Four of 23 suppliers lacked sterile compounding licenses and four had disciplinary records.
Covers: Compounded semaglutide and tirzepatide
Source: American Med Spa Association on JAMA Health Forum study, Jul 2026
Concierge and longevity doctors
Cash-pay physicians build peptide plans for wealthy clients. Reporting from San Francisco says some source from overseas channels, domestic research-use-only sellers or the few compounding pharmacies that will supply clinicians.
Risk: A doctor's involvement does not guarantee a pharmaceutical-grade product.
Covers: BPC-157, thymosin alpha-1, Selank, Semax, CJC-1295, ipamorelin, retatrutide
Source: San Francisco Standard, Sep 2025
Cross-border purchase or import
FDA says importing drugs for personal use is illegal in most cases but it may not object to small personal quantities in limited situations. Reporting also describes people travelling to Mexico for injections.
Risk: Packages can be seized. Product origin and cold-chain handling are hard to check.
Covers: Approved prescription peptides sold abroad
Source: FDA, personal importation
Routes people use for any peptide in the United States
Research-chemical websites
Sites sell vials marked for research or not for human consumption, with no prescription. FDA says some ship direct to consumers with dosing directions, and it has sent warning letters. Retatrutide exists only through this route or trials.
Risk: Unknown identity, strength and sterility. No pharmacist or prescriber involved.
Covers: Retatrutide, semaglutide, tirzepatide, BPC-157 and most unapproved peptides
Source: FDA, unapproved GLP-1 drugs page
Direct orders from Chinese factories
Buyers message factory sales agents and pay by crypto or payment app. A minimum order of about ten vials pushes people to buy in bulk and share. A blockchain analysis found US buyers were the largest source of funds.
Risk: Many of the same vendors list fentanyl precursors. Lab reports sent by sellers cannot be verified.
Covers: GLP-1 copies, melanotan II, BPC-157, TB-500, GHK-Cu, epitalon
Source: TRM Labs, Oct 2026
Chat groups and social sellers
Dealers are found through Telegram, WhatsApp, Discord and influencer discount codes. In a May 2026 survey of 1,000 US users, 14.5 percent bought this way and three quarters asked an AI chatbot for dosing.
Risk: 45 percent of social media buyers in that survey reported an emergency or urgent care visit for a reaction.
Covers: Retatrutide and other research-use-only peptides
Source: The Ethos, May 2026
This describes what people do. It is not advice. The decision is yours.
More contextCase reports, what public figures say, videos and articles, when options run out and the chemistry
Case reports
From journals, regulators and studies of users. One case proves little.
Benefit reportedcase series - 39 people - 2020
Swiss adults with EPP went from a median of 10 pain-free minutes in sun to 180 minutes on treatment. Quality-of-life scores rose sharply. Two stopped, neither for drug-related harm.
Mixed resultcase series - 200 people - 2025
German registry of EPP patients, 2016 to 2021, funded by the manufacturer. Quality of life improved in most periods and 91 percent stayed on treatment. 54 percent had a related side effect, mostly nausea or headache. Four had serious ones.
Source: Porphyria News, 2025-03
What experts and influencers say
Paraphrased from the linked sources.
Appealed the NICE rejection alongside the manufacturer. The panel upheld one point: delays in the evaluation were procedurally unfair. The negative recommendation stood.
Said it was immensely disappointed after NICE confirmed in 2023 that patients in England would not get the implant on the NHS.
Source: Pharmaphorum, 2023-07
British Porphyria AssociationSourceRecommends
Accepted the drug is effective for EPP but declined to recommend NHS funding, calling the size of benefit uncertain and cost-effectiveness analysis very challenging.
Source: Pharmaphorum, 2023-07
Announced acceptance of the implant for NHS Scotland through the ultra-orphan pathway for three years while more data is gathered. Said it may let patients spend longer outdoors.
Source: STV News, 2021-02
Mark MacGregorWebsiteRecommends
Photo source: nhsscotlandevents.com
Said Health Canada took a long time to approve the drug and pointed to its long-term safety record as its edge over other EPP drugs in development.
Dennis WrightWebsiteRecommends
Money: Executive of the manufacturer
Photo source: clinuvel.com
Reported that Swiss patients tolerated far more sunlight on treatment, and that half the cohort had treatment interrupted in 2016-2017 because insurers denied reimbursement.
Jasmin Barman-Aksozen and colleaguesSourceRecommends
Money: Hospital foundation grant; one author is vice-president of a patient network
Watch and read
Explainers, reporting and podcasts worth your time. Summaries are ours. No sellers.
How a patient helped shape a treatment for a rare skin disorder
Jenna Philpott, reporter
A patient with EPP explains how she helped design afamelanotide (Scenesse) trials and addressed European regulators, and why she wants head-to-head comparisons for new drugs.
Patient's-eye view of the approved medical use.
Revealed: Hidden dangers behind trend of tanning drops, sprays and injections
Investigation into influencer-promoted tanning products, finding many contain Melanotan II, an unregulated relative of afamelanotide, and may cause serious harm.
Warning about the unregulated tanning-peptide market.
When options run out
Uses people turn to when standard treatment has failed.
Variegate porphyria skin fragility
- Who
- Adults with variegate porphyria and active blistering skin disease, who have no approved skin treatment.
- Evidence
- One company-run pilot in six patients with no control arm. All improved on a physician-rated global scale over six months and median skin lesion count fell from 10.5 to 3. Side effects were mild or moderate. Larger trials were proposed.
- Route
- Company phase 2 trial
Source: Clinuvel announcement, 2024-03
Xeroderma pigmentosum photoprotection
- Who
- People with a DNA repair disorder who burn and develop skin cancers from minimal UV exposure.
- Evidence
- Company-reported lab findings from the first three patients: less UV-induced DNA damage and less sunburn under lab conditions. No clinical outcome data, and skin cancer prevention is not shown.
- Route
- Company clinical trial
Source: Biotech Dispatch, 2023-01
Vitiligo repigmentation with light therapy
- Who
- People with darker skin types and vitiligo, combined with narrowband UVB phototherapy.
- Evidence
- A phase 3 trial of 210 patients is running with topline data expected December 2026. A second trial of 300 is planned.
- Route
- Phase 3 trials
Source: Kalkine Media, 2026-07
Legal last-resort routes
Expanded access (compassionate use)
For a serious or life-threatening condition with no comparable alternative and no trial you can join. Your physician asks the company for the drug, then files with FDA and an ethics board. The company can refuse. Costs are often not insured.
Right to Try
For a life-threatening condition after approved options are exhausted and no trial is open to you. The drug must have finished Phase 1 and be in active development. Your doctor asks the manufacturer directly. FDA does not review requests.
Source: FDA, Right to Try
Trial finders
Search ClinicalTrials.gov by condition or drug name, check eligibility and call the listed site. ResearchMatch is a free NIH-funded registry that lets researchers find you. Discuss risks with your own clinician before enrolling.
Source: NIH, finding a clinical trial
Personal import for serious conditions
FDA may not object when a US citizen imports up to about three months of a drug for a serious condition with no effective US treatment, with written personal-use confirmation and a US doctor's details. It is discretion, not a right.
Source: FDA, personal importation
Patient-specific compounding
When the approved product cannot meet a specific need of an identified patient, a prescriber can order a compounded version from a licensed pharmacy. Lower price alone does not qualify. Ingredients must be pharmaceutical grade.
Amino-acid sequence
Striped tiles are mirror-image (D) amino acids, which resist breakdown. Ringed tiles are amino acids not found in natural proteins.
Questions people ask
What is Scenesse used for?
Sun tolerance in erythropoietic protoporphyria (EPP), a rare light-sensitivity disease. In a six-month trial, people managed a median of 64 pain-free hours in direct sun, against 41 on placebo.
Is afamelanotide the same as Melanotan I?
Yes, Melanotan I is another name for afamelanotide. It is the licensed relative of the tanning injections and is not approved for cosmetic tanning anywhere.
How is afamelanotide given?
As a slow-release implant placed under the skin every two months by a trained professional. The EU limits it to four implants a year.
What are the side effects of Scenesse?
Reactions at the implant site (21%) and nausea (19%) are common. It darkens moles and freckles, so the label recommends a full-body skin check twice a year, and rare severe allergic reactions have been reported.
Your notebook
Taking it? A ten-second daily check-in keeps a record of how you feel, to talk through with your clinician.
Sources
Structure: PubChem